NCT04631744 is a Phase 2 clinical trial of Cabozantinib in Prostate Cancer, sponsored by Weill Medical College of Cornell University.

Who is sponsoring NCT04631744?

NCT04631744 is sponsored by Weill Medical College of Cornell University.

What drugs are being tested in NCT04631744?

Interventions in NCT04631744: Cabozantinib.

What condition does NCT04631744 study?

NCT04631744 studies Prostate Cancer.

Is NCT04631744 still recruiting?

NCT04631744 is currently completed. Last updated 18 December 2025.

Last reviewed 2025-12-18 · How we verify

NCT04631744

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Completed Phase 2 Last updated 18 December 2025

What this trial tests

Phase 2 trial testing Cabozantinib in Prostate Cancer in 4 participants. Completed in 9 November 2025.

Timeline

3 March 2021

Primary endpoint
12 May 2025

9 November 2025

Quick facts

Lead sponsor	Weill Medical College of Cornell University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	3 March 2021
Primary completion	12 May 2025
Estimated completion	9 November 2025
Sites	1 location across United States

Drugs / interventions tested

Cabozantinib (CABOZANTINIB) — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Weill Medical College of Cornell University

Who can join

Adults 18 to 99, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Therapy considerations in neuroendocrine prostate cancer: what next?
Beltran H, Demichelis F. · · 2021 · cited 74× · PMID 34111024 · DOI 10.1530/erc-21-0140
Cabozantinib for the treatment of solid tumors: a systematic review.
Maroto P, Porta C, Capdevila J, Apolo AB, et al · · 2022 · cited 38× · PMID 35847482 · DOI 10.1177/17588359221107112
Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer - Narrowing the Gap Between Bench and Bedside.
Solimando AG, Kalogirou C, Krebs M. · · 2022 · cited 15× · PMID 35222436 · DOI 10.3389/fimmu.2022.842038
Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.
Zamora I, Freeman MR, Encío IJ, Rotinen M. · · 2023 · cited 10× · PMID 37761978 · DOI 10.3390/ijms241813673
The Value of Phenotypic Precision Medicine in Prostate Cancer.
Hawkey NM, Broderick A, George DJ, Sartor O, et al · · 2023 · cited 9× · PMID 36200788 · DOI 10.1093/oncolo/oyac198
Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y
New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic.
Cai M, Zheng F, Ren YZ, Zhen C, et al · · 2025 · cited 2× · PMID 40746825 · DOI 10.34133/research.0791

Verify or expand the search:

Other trials of Cabozantinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07187869 — Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell · Phase 1 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06900595 — Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent · Phase 2 · recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04631744 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
Last refreshed: 18 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04631744.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing